Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recordati SpA
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bouchara Recordati
- Dr. F. Frik Ilaç A.S.
- Opalia Pharma S.A.
- Orphan Europe
- Recordati Pharmaceuticals Ltd.
- Laboratorios Casen Fleet
- Italchimici S.p.A.
- Pro Farma AG
- Recordati S.A. Chemical and Pharmaceutical Company
- Recordati Rare Diseases Canada Inc.
- Natural Point S.r.l.
- Tonipharm S.A.S.
- FIMEI S.p.A
- Rossini Investimenti S.p.A